Sanofi Tolebrutinib setback includes a Phase 3 failure in primary progressive MS and a delayed US approval decision.
Author: PharmaSignal News Desk
Arcus Gilead trial cancellation marks a setback in cancer research as the TIGIT/PD-1 study is halted for futility, impacting future strategies.
Praxis epilepsy drug approval filing is planned for early 2025 after collaborative discussions with the FDA. Rezolute shares fell, Centessa named a new CEO.
AC Immune Parkinson’s drug shows positive data, prompting regulatory feedback request. Shares rise by double-digits.
Apple Tree Ventures files for bankruptcy amid a funding dispute with billionaire backer, affecting its startups and restructuring plans.
Lilly retatrutide obesity drug demonstrates up to 29% weight loss in Phase 3 study, setting a new benchmark for competitors.
ACA subsidy alternative proposed by Crapo and Cassidy aims to enhance health savings accounts for bronze or catastrophic plans.
Prolynx obesity drugs aim to use novel linker technology for monthly or quarterly administration, backed by a $70M Series A funding.
FDA Approves Augmentin XR, marking the first drug in the National Priority Voucher program, enhancing antibiotic availability in the US.
PsiThera, formerly Psivant Therapeutics, raises $47M for AI-designed oral drugs targeting immune conditions.